NXTC executed a significant reverse stock split reducing outstanding shares from 28M to 3.6M while burning through substantial cash reserves amid mounting operating losses.
The dramatic share count reduction from 28 million to 3.6 million shares indicates a reverse stock split likely aimed at maintaining Nasdaq compliance, though previous language about non-compliance was removed. The company's financial position deteriorated meaningfully with stockholders' equity declining 47% to $34.9M and total assets falling 38% to $50.2M, signaling accelerated cash burn in this clinical-stage biotech.
NXTC's balance sheet contracted substantially across all major categories, with current assets falling 39% to $43.7M and stockholders' equity declining 47% to $34.9M. Operating cash outflows worsened to -$49.6M from -$40.8M in the prior year, while capital expenditures were reduced 42% to $474K. The overall financial picture shows a clinical-stage company aggressively managing cash burn while pursuing development programs, though the accelerating losses and shrinking asset base raise questions about funding runway.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Capex reduced 42.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Current assets declined 39.1% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 37.9% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Current liabilities rose 10.4% — increased short-term obligations, watch current ratio.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →